Summary & Overview
HCPCS J1833: Injection, Isavuconazonium, 1 mg
HCPCS Level II code J1833 designates the injection of isavuconazonium, billed per 1 mg of drug. This code captures administration of an intravenous antifungal agent used in the treatment of invasive fungal infections, a clinically significant area given rising rates of serious fungal disease and high-cost specialty therapeutics. Nationally, accurate coding for antifungal infusions affects claims processing, utilization tracking, and reimbursement for hospitals and outpatient infusion centers.
Key payers relevant to this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J1833, common payer coverage considerations, and expected places of service for billing. The publication outlines benchmarks for utilization and reimbursement patterns where available, summarizes recent policy or coverage updates affecting parenteral antifungal billing, and highlights coding considerations specific to HCPCS Level II drug units.
This summary is intended for revenue cycle professionals, clinical billing staff, and policy analysts who need a national-level briefing on HCPCS Level II code J1833, its clinical use, and payer relevance. Data not available in the input for certain specifics such as associated taxonomies, ICD-10 pairings, and related codes.
Billing Code Overview
HCPCS Level II code J1833 represents the injection of isavuconazonium, billed per 1 mg of drug. The service involves administration of an intravenous antifungal agent indicated for invasive fungal infections.
Service Type: Parenteral drug administration (intravenous infusion or injection)
Typical Site of Service: Hospital outpatient department, inpatient hospital, or other clinical infusion settings
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is a hospitalized adult with invasive mold infection (such as invasive aspergillosis or mucormycosis) or an immunocompromised outpatient requiring targeted systemic antifungal therapy. The patient often presents with persistent fever, pulmonary infiltrates on chest imaging, or positive fungal cultures/biopsy. After infectious disease consultation, the clinician orders intravenous isavuconazonium (prodrug of isavuconazole) for treatment or step-down therapy when oral administration is not feasible.
Clinical workflow: Admission or infusion center visit → baseline labs (liver function tests, electrolytes) and review of drug interactions → pharmacy prepares dose based on vial strength and converts to active drug milligram equivalents (J1833 is billed per 1 mg of isavuconazonium) → nurse administers IV infusion per institutional protocol (including infusion time and monitoring for infusion reactions) → documentation of indication, dose, lot number, and any adverse reactions → outpatient infusion visits or discharge with oral isavuconazole formulation when appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no modifier applies and the service is reported unmodified |